Base de dados : MEDLINE
Pesquisa : D02.033.100.291.425 [Categoria DeCS]
Referências encontradas : 1483 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 149 ir para página                         

  1 / 1483 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28835457
[Au] Autor:Roewe J; Higer M; Riehl DR; Gericke A; Radsak MP; Bosmann M
[Ad] Endereço:Center for Thrombosis and Hemostasis, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
[Ti] Título:Neuroendocrine Modulation of IL-27 in Macrophages.
[So] Source:J Immunol;199(7):2503-2514, 2017 Oct 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Heterodimeric IL-27 (p28/EBV-induced gene 3) is an important member of the IL-6/IL-12 cytokine family. IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms. There is a great body of evidence on the bidirectional interplay between the autonomic nervous system and immune responses during inflammatory disorders, but so far IL-27 has not been defined as a part of these multifaceted neuroendocrine networks. In this study, we describe the role of catecholamines (as mediators of the sympathetic nervous system) related to IL-27 production in primary mouse macrophages. Noradrenaline and adrenaline dose-dependently suppressed the release of IL-27p28 in LPS/TLR4-activated macrophages, which was independent of α adrenoceptors. Instead, ß adrenoceptor activation was responsible for mediating gene silencing of IL-27p28 and EBV-induced gene 3. The ß adrenoceptor agonists formoterol and salbutamol mediated suppression of IL-27p28 production, when triggered by zymosan/TLR2, LPS/TLR4, or R848/TLR7/8 activation, but selectively spared the polyinosinic-polycytidylic acid/TLR3 pathway. Mechanistically, ß adrenergic signaling reinforced an autocrine feedback loop of macrophage-derived IL-10 and this synergized with inhibition of the JNK pathway for limiting IL-27p28. The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80 CD11b macrophages. In endotoxic shock of C57BL/6J mice, pharmacologic activation of ß adrenoceptors improved the severity of shock, including hypothermia and decreased circulating IL-27p28. Conversely, IL-27p28 was 2.7-fold increased by removal of the catecholamine-producing adrenal glands prior to endotoxic shock. These data suggest a novel role of the sympathetic neuroendocrine system for the modulation of IL-27-dependent acute inflammation.
[Mh] Termos MeSH primário: Epinefrina/farmacologia
Interleucinas/imunologia
Interleucinas/metabolismo
Macrófagos/efeitos dos fármacos
Macrófagos/imunologia
Norepinefrina/farmacologia
[Mh] Termos MeSH secundário: Albuterol/farmacologia
Animais
Antracenos/farmacologia
Células Cultivadas
Fumarato de Formoterol/farmacologia
Inflamação
Interleucina-10/biossíntese
Interleucina-10/imunologia
Interleucinas/sangue
Interleucinas/genética
Lipopolissacarídeos/farmacologia
Ativação de Macrófagos/efeitos dos fármacos
Camundongos
Camundongos Endogâmicos C57BL
Poli I-C/metabolismo
Receptores Adrenérgicos/efeitos dos fármacos
Choque Séptico
Transdução de Sinais/efeitos dos fármacos
Sulfonamidas/farmacologia
Sistema Nervoso Simpático/imunologia
Sistema Nervoso Simpático/fisiologia
Tiadiazóis/farmacologia
Receptor 3 Toll-Like/metabolismo
Zimosan/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AEG 3482); 0 (Anthracenes); 0 (Il27 protein, mouse); 0 (Interleukins); 0 (Lipopolysaccharides); 0 (Receptors, Adrenergic); 0 (Sulfonamides); 0 (Thiadiazoles); 0 (Toll-Like Receptor 3); 130068-27-8 (Interleukin-10); 1TW30Y2766 (pyrazolanthrone); 9010-72-4 (Zymosan); O84C90HH2L (Poly I-C); QF8SVZ843E (Albuterol); W34SHF8J2K (Formoterol Fumarate); X4W3ENH1CV (Norepinephrine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700687


  2 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28832630
[Au] Autor:Lin YH; Liao XN; Fan LL; Qu YJ; Cheng DY; Shi YH
[Ad] Endereço:Department of Respiratory Medicine, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
[Ti] Título:Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D.
[So] Source:PLoS One;12(8):e0183300, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The systemic inflammation is associated with clinical outcome and mortality in chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of tiotropium (Tio) and/or budesonide/formoterol (Bud/Form) on systemic inflammation biomarkers in stable COPD patients of group D, a randomized, open-label clinical trial was conducted. METHODS: Eligible participants (n = 324) were randomized and received either Tio 18ug once daily (group I), Bud/Form 160/4.5ug twice daily (group II), Bud/Form 320/9ug twice daily (group III), or Tio 18ug once daily with Bud/Form 160/4.5ug twice daily (group IV) for 6 months. Systemic inflammation biomarkers were measured before randomization and during the treatment, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), tumor necrosis factor-α (TNF-α), fibrinogen (Fib), and white blood cell (WBC). RESULTS: After 6-month treatment, CRP levels in group II, group III and group IV changed by a median (interquartile range) of -1.25 (-3.29, 1.18) mg/L, -1.13 (-2.55, 0.77) mg/L, and -1.56 (-4.64, 0.22) mg/L respectively, all of which with statistical differences compared with group I. In addition, there were no treatment differences in terms of IL-8, SAA, TNF-α, Fib and WBC levels. CONCLUSIONS: A long-term treatment with Bud/Form alone or together with Tio can attenuate circulating CRP levels in COPD patients of group D, compared with Tio alone.
[Mh] Termos MeSH primário: Broncodilatadores/uso terapêutico
Budesonida/uso terapêutico
Proteína C-Reativa/metabolismo
Fumarato de Formoterol/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Biomarcadores/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 0 (Bronchodilator Agents); 51333-22-3 (Budesonide); 9007-41-4 (C-Reactive Protein); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183300


  3 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28757318
[Au] Autor:Self TH; Ellingson S
[Ad] Endereço:University of Tennessee Health Science Center, Methodist University Hospital, Memphis. Electronic address: tself@uthsc.edu.
[Ti] Título:New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler.
[So] Source:Am J Med;130(11):1251-1254, 2017 Nov.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered-dose inhaler was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of 3 delivery systems for LAMA/LABA therapy, including metered-dose inhaler, dry-powder inhaler, and Soft Mist inhaler. On the basis of numerous patient factors, such as cognitive ability, manual strength/dexterity, and peak inspiratory flow, clinicians may select the most appropriate inhalation device. For each inhalation device, persistent patient education is absolutely essential, including observation of patient use. International evidence-based guidelines stress the critical importance of ensuring correct use of inhalation devices.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Fumarato de Formoterol/farmacologia
Glicopirrolato/farmacologia
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Broncodilatadores/farmacologia
Preparações de Ação Retardada/farmacologia
Combinação de Medicamentos
Seres Humanos
Antagonistas Muscarínicos/farmacologia
Nebulizadores e Vaporizadores
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Bronchodilator Agents); 0 (Delayed-Action Preparations); 0 (Drug Combinations); 0 (Muscarinic Antagonists); V92SO9WP2I (Glycopyrrolate); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE


  4 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28703592
[Au] Autor:Yan S; Shaw DE; Yang L; Sandham DA; Healy MP; Reilly J; Wang B
[Ad] Endereço:Global Discovery Chemistry, Novartis Institutes for BioMedical Research , Cambridge, Massachusetts 02139, United States.
[Ti] Título:Interactions between ß2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR.
[So] Source:J Med Chem;60(16):6867-6879, 2017 Aug 24.
[Is] ISSN:1520-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To understand the relationship between structural properties of the ß2-adrenoceptor ligands and their interactions with membranes, we have investigated the location and distribution of five ß2 agonists with distinct clinical durations and onsets of action (indacaterol, two indacaterol analogues, salmeterol and formoterol) in monounsaturated model membranes using magic angle spinning NMR to measure these interactions through both H nuclear Overhauser enhancement (NOE) and paramagnetic relaxation enhancement (PRE) techniques. The hydrophilic aromatic groups of all five ß2 agonists show maximum distribution in the lipid/water interface, but distinct location and dynamic behavior were observed for the lipophilic aromatic rings. Our study elucidates at atomic level that the hydrophobicity and substitution geometry of lipophilic groups play important roles in compound-lipid interactions.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/química
Lipossomos/química
[Mh] Termos MeSH secundário: Fumarato de Formoterol/química
Interações Hidrofóbicas e Hidrofílicas
Indanos/química
Ligantes
Espectroscopia de Ressonância Magnética
Fosfatidilcolinas/química
Quinolonas/química
Xinafoato de Salmeterol/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Indans); 0 (Ligands); 0 (Liposomes); 0 (Phosphatidylcholines); 0 (Quinolones); 6EW8Q962A5 (Salmeterol Xinafoate); 8OR09251MQ (indacaterol); TE895536Y5 (1-palmitoyl-2-oleoylphosphatidylcholine); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jmedchem.7b00205


  5 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28443352
[Au] Autor:Rabe KF
[Ad] Endereço:a LungenClinic Grosshansdorf, Airway Research Center North , Member of the German Center for Lung Research (DZL) , Grosshansdorf , Germany.
[Ti] Título:GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
[So] Source:Expert Rev Clin Pharmacol;10(7):685-698, 2017 Jul.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and incidence rates are continuing to rise. Long-acting bronchodilators are the foundation on which current pharmacological approaches to COPD management are built, with long-acting muscarinic antagonists (LAMAs) and long-acting ß -agonists (LABAs) recommended across the spectrum of the disease continuum. Combining LAMAs and LABAs provides additional lung function improvements and relief of patient symptoms compared with either therapy alone. Several options for LAMA/LABA fixed-dose combinations (FDC) delivered via a single inhaler device are available; however, only recently has a LAMA/LABA FDC become available as a pressurized metered dose inhaler (MDI). Areas covered: This article describes the rationale for the development of the LAMA/LABA FDC of glycopyrrolate and formoterol fumarate, formulated by Co-Suspension™ Delivery Technology and delivered by MDI (GFF MDI). The clinical trial program of GFF MDI, including the pivotal Phase III studies (PINNACLE-1 and PINNACLE-2) that supported regulatory approval, are reviewed, providing insights into interpretation and future directions for research. Expert commentary: LAMA/LABA FDCs are already a crucial part of the COPD treatment paradigm, but additional data are needed in order to maximize their role as maintenance therapies in patients with COPD.
[Mh] Termos MeSH primário: Broncodilatadores/administração & dosagem
Fumarato de Formoterol/administração & dosagem
Glicopirrolato/administração & dosagem
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Agonistas de Receptores Adrenérgicos beta 2/farmacologia
Broncodilatadores/farmacologia
Preparações de Ação Retardada
Combinação de Medicamentos
Sistemas de Liberação de Medicamentos
Fumarato de Formoterol/farmacologia
Glicopirrolato/farmacologia
Seres Humanos
Inaladores Dosimetrados
Antagonistas Muscarínicos/administração & dosagem
Antagonistas Muscarínicos/farmacologia
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Bronchodilator Agents); 0 (Delayed-Action Preparations); 0 (Drug Combinations); 0 (Muscarinic Antagonists); V92SO9WP2I (Glycopyrrolate); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1320218


  6 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28427362
[Au] Autor:Jenkins CR; Eriksson G; Bateman ED; Reddel HK; Sears MR; Lindberg M; O'Byrne PM
[Ad] Endereço:Department of Thoracic Medicine, Concord Hospital and The George Institute for Global Health, PO Box M201, Missenden Rd, Sydney, NSW, 2050, Australia. christine.jenkins@sydney.edu.au.
[Ti] Título:Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.
[So] Source:BMC Pulm Med;17(1):65, 2017 Apr 20.
[Is] ISSN:1471-2466
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Asthma management may involve a step up in treatment when symptoms are not well controlled. We examined whether budesonide/formoterol maintenance and reliever therapy (MRT) is as effective as higher, fixed-dose budesonide plus as-needed terbutaline in patients requiring step-up from Step 2 treatment (low-dose inhaled corticosteroids), stratified by baseline reliever use. METHODS: A post-hoc analysis utilized data from three clinical trials of 6-12 months' duration. Patients aged ≥12 years with symptomatic asthma uncontrolled despite Step 2 treatment were included. Severe exacerbation rate, lung function and reliever use were analysed, stratified by baseline reliever use (<1, 1-2 and >2 occasions/day). RESULTS: Overall, 1239 patients were included. Reductions in severe exacerbation rate with budesonide/formoterol MRT versus fixed-dose budesonide were similar across baseline reliever use levels, and were statistically significant in patients using 1-2 (42%, p = 0.01) and >2 (39%, p = 0.02) reliever occasions/day, but not <1 reliever occasion/day (35%, p = 0.11). Both treatments significantly increased mean FEV from baseline; improvements were significantly greater for budesonide/formoterol MRT in all reliever use groups. Reductions in reliever use from baseline were significantly greater with budesonide/formoterol MRT versus fixed-dose budesonide in patients using 1-2 and >2 reliever occasions/day (-0.33 and -0.74 occasions/day, respectively). CONCLUSIONS: Treatment benefit with budesonide/formoterol MRT versus higher, fixed-dose budesonide plus short-acting ß -agonist was found in Step 2 patients with relatively low reliever use, supporting the proposal that budesonide/formoterol MRT may be useful when asthma is uncontrolled with low-dose inhaled corticosteroid.
[Mh] Termos MeSH primário: Corticosteroides/administração & dosagem
Asma/tratamento farmacológico
Budesonida/administração & dosagem
Fumarato de Formoterol/administração & dosagem
Terbutalina/administração & dosagem
[Mh] Termos MeSH secundário: Administração por Inalação
Adolescente
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Adulto
Idoso
Idoso de 80 Anos ou mais
Antiasmáticos/administração & dosagem
Austrália
Criança
Pré-Escolar
Método Duplo-Cego
Combinação de Medicamentos
Quimioterapia Combinada
Feminino
Seres Humanos
Pulmão/fisiopatologia
Masculino
Meia-Idade
Análise de Regressão
Terapia Respiratória/métodos
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Adrenergic beta-2 Receptor Agonists); 0 (Anti-Asthmatic Agents); 0 (Drug Combinations); 51333-22-3 (Budesonide); N8ONU3L3PG (Terbutaline); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE
[do] DOI:10.1186/s12890-017-0401-y


  7 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28385164
[Au] Autor:Sauer R; Griff S; Blau A; Franke A; Mairinger T; Grah C
[Ad] Endereço:Institute of Pathology, HELIOS Klinikum Emil von Behring, Walterhöferstr. 11, Berlin, 14165, Germany. rica.sauer@helios-kliniken.de.
[Ti] Título:Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia diagnosed by transbronchial lung cryobiopsy: a case report.
[So] Source:J Med Case Rep;11(1):95, 2017 Apr 07.
[Is] ISSN:1752-1947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Micronodular lesions are common findings in lung imaging. As an important differential diagnosis, we describe a case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia; it is notable that the diagnosis of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia is often delayed. This case provides supporting evidence to establish lung biopsy by cryotechnique as the option of first choice when considering a diagnostic strategy for micronodular lung lesions. CASE PRESENTATION: We report a case of a 65-year-old white woman who presented with obstructive symptoms of chronic coughing and dyspnea confirmed by conventional lung function tests. A computed tomography scan presented disseminated micronodules in all the lobes of her lungs. With the help of bronchoscopic cryobiopsy it was possible to obtain a high yield sample of lung parenchyma. On histologic examination, the micronodules correlated with a diffuse neuroendocrine cell hyperplasia. In the context of clinical symptoms, radiological aspects, and histomorphological aspects we made the diagnosis of a diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Obstructive symptoms were treated with inhaled steroids and beta-2-mimetics continuously. A comparison between current computed tomography scans of our patient and scans of 2014 revealed no significant changes. Last ambulatory checks occurred in January and May of 2016. The course of disease and the extent of limitation of lung function have remained stable. CONCLUSIONS: The diagnosis of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia is best made in a multidisciplinary review including clinical presentation, lung imaging, and histomorphological aspects. This report and current literature indicate that transbronchial lung cryobiopsy can be used as a safe and practicable tool to obtain high quality biopsies of lung parenchyma in order to diagnose micronodular lesions of the lung.
[Mh] Termos MeSH primário: Criocirurgia
Hiperplasia/diagnóstico
Doenças Pulmonares Intersticiais/diagnóstico
Pulmão/patologia
Células Neuroendócrinas/patologia
Cirurgia Torácica Vídeoassistida
Tomografia Computadorizada por Raios X
[Mh] Termos MeSH secundário: Idoso
Albuterol/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Biópsia/instrumentação
Broncodilatadores/uso terapêutico
Budesonida/uso terapêutico
Tosse/etiologia
Criocirurgia/métodos
Dispneia/etiologia
Feminino
Fumarato de Formoterol/uso terapêutico
Seres Humanos
Hiperplasia/tratamento farmacológico
Hiperplasia/patologia
Doenças Pulmonares Intersticiais/tratamento farmacológico
Doenças Pulmonares Intersticiais/patologia
Prognóstico
Testes de Função Respiratória
Brometo de Tiotrópio/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Bronchodilator Agents); 51333-22-3 (Budesonide); QF8SVZ843E (Albuterol); W34SHF8J2K (Formoterol Fumarate); XX112XZP0J (Tiotropium Bromide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1186/s13256-017-1254-y


  8 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28375647
[Au] Autor:Lipson DA; Barnacle H; Birk R; Brealey N; Locantore N; Lomas DA; Ludwig-Sengpiel A; Mohindra R; Tabberer M; Zhu CQ; Pascoe SJ
[Ad] Endereço:1 GlaxoSmithKline, King of Prussia, Pennsylvania.
[Ti] Título:FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
[So] Source:Am J Respir Crit Care Med;196(4):438-446, 2017 Aug 15.
[Is] ISSN:1535-4970
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting ß -agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited. OBJECTIVES: We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD. METHODS: The FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 µg/62.5 µg/25 µg; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 µg/12 µg; Turbuhaler). A patient subgroup remained on blinded treatment for up to 52 weeks. Co-primary endpoints were change from baseline in trough FEV and in St. George's Respiratory Questionnaire (SGRQ) total score at Week 24. MEASUREMENTS AND MAIN RESULTS: In the intent-to-treat population (n = 1,810) at Week 24 for triple therapy (n = 911) and ICS/LABA therapy (n = 899), mean changes from baseline in FEV were 142 ml (95% confidence interval [CI], 126 to 158) and -29 ml (95% CI, -46 to -13), respectively, and mean changes from baseline in SGRQ scores were -6.6 units (95% CI, -7.4 to -5.7) and -4.3 units (95% CI, -5.2 to -3.4), respectively. For both endpoints, the between-group differences were statistically significant (P < 0.001). There was a statistically significant reduction in moderate/severe exacerbation rate with triple therapy versus dual ICS/LABA therapy (35% reduction; 95% CI, 14-51; P = 0.002). The safety profile of triple therapy reflected the known profiles of the components. CONCLUSIONS: These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in patients with advanced COPD. Clinical trial registered with www.clinicaltrials.gov (NCT02345161).
[Mh] Termos MeSH primário: Androstadienos/uso terapêutico
Álcoois Benzílicos/uso terapêutico
Budesonida/uso terapêutico
Clorobenzenos/uso terapêutico
Fumarato de Formoterol/uso terapêutico
Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico
Quinuclidinas/uso terapêutico
[Mh] Termos MeSH secundário: Administração por Inalação
Broncodilatadores/uso terapêutico
Método Duplo-Cego
Esquema de Medicação
Quimioterapia Combinada
Feminino
Volume Expiratório Forçado/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
Nebulizadores e Vaporizadores
Qualidade de Vida
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androstadienes); 0 (Benzyl Alcohols); 0 (Bronchodilator Agents); 0 (Chlorobenzenes); 0 (GSK573719); 0 (Quinuclidines); 028LZY775B (vilanterol); 51333-22-3 (Budesonide); JS86977WNV (fluticasone furoate); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.1164/rccm.201703-0449OC


  9 / 1483 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28283554
[Au] Autor:Kobayashi Y; Ito K; Kanda A; Tomoda K; Mercado N; Barnes PJ
[Ad] Endereço:Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom (Y.K., K.I., N.M., P.J.B.); and Airway Disease Section, Department of Otolaryngology, Kansai Medical University, Moriguchi, Osaka, Japan (Y.K., A.K., K.T.).
[Ti] Título:Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity.
[So] Source:Mol Pharmacol;91(5):475-481, 2017 May.
[Is] ISSN:1521-0111
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We have reported that phosphorylation of the glucocorticoid receptor (GR) at Ser reduces GR nuclear translocation, resulting in corticosteroid insensitivity in patients with severe asthmas. A serine/threonine protein phosphatase 2A, which regulates c-Jun N-terminal kinase (JNK) 1 and GR-Ser signaling, is involved in this mechanism. Here, we further explored protein kinase dual-specificity phosphatases (DUSPs) with the ability to dephosphorylate JNK, and identified DUSP4 as a phosphatase involved in the regulation of corticosteroid sensitivity. The effects of knocking down DUSPs (DUSP1, 4, 8, 16, and 22) by small interfering RNA (siRNA) were evaluated in a monocytic cell line (U937). Corticosteroid sensitivity was determined by dexamethasone enhancement of FK506-binding protein 51 or inhibition of tumor necrosis factor (TNF )-induced interferon and interleukin 8 expression and GR translocation from cell cytoplasm to nucleus. The nuclear/cytoplasmic GR, phosphorylation levels of GR-Ser and JNK1, coimmunoprecipitated GR-JNK1-DUSP4, and DUSP4 expression were analyzed by western blotting and/or imaging flow cytometry. Phosphatase activity of immunoprecipitated (IP)-DUSP4 was measured by fluorescence-based assay. Knockdown of DUSP4 enhanced phosphorylation of GR-Ser and JNK1 and reduced GR nuclear translocation and corticosteroid sensitivity. Coimmunoprecipitation experiments showed that DUSP4 is associated with GR and JNK1. In peripheral blood mononuclear cells from severe asthmatics, DUSP4 expression was reduced versus healthy subjects and negatively correlated with phosphorylation levels of GR-Ser and JNK1. Formoterol enhanced DUSP4 activity and restored corticosteroid sensitivity reduced by DUSP4 siRNA. In conclusion, DUSP4 regulates corticosteroid sensitivity via dephosphorylation of JNK1 and GR-Ser DUSP4 activation by formoterol restores impaired corticosteroid sensitivity, indicating that DUSP4 is crucial in regulating corticosteroid sensitivity, and therefore might be a novel therapeutic target in severe asthma.
[Mh] Termos MeSH primário: Corticosteroides/farmacologia
Fosfatases de Especificidade Dupla/metabolismo
Fosfatases da Proteína Quinase Ativada por Mitógeno/metabolismo
[Mh] Termos MeSH secundário: Asma/sangue
Asma/enzimologia
Asma/patologia
Feminino
Fumarato de Formoterol/farmacologia
Seres Humanos
Leucócitos Mononucleares/efeitos dos fármacos
Leucócitos Mononucleares/metabolismo
Masculino
Meia-Idade
Transporte Proteico/efeitos dos fármacos
RNA Interferente Pequeno/metabolismo
Receptores de Glucocorticoides/metabolismo
Células U937
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (RNA, Small Interfering); 0 (Receptors, Glucocorticoid); EC 3.1.3.16 (Mitogen-Activated Protein Kinase Phosphatases); EC 3.1.3.48 (DUSP4 protein, human); EC 3.1.3.48 (Dual-Specificity Phosphatases); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170312
[St] Status:MEDLINE
[do] DOI:10.1124/mol.116.107656


  10 / 1483 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28256307
[Au] Autor:Pearlman DS; Eckerwall G; McLaren J; Lamarca R; Puu M; Gilbert I; Jorup C; Sandin K; Lanz MJ
[Ad] Endereço:Colorado Allergy & Asthma Centers, P.C., Denver, Colorado. Electronic address: ds.pearlman@coloradoallergy.com.
[Ti] Título:Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
[So] Source:Ann Allergy Asthma Immunol;118(4):489-499.e1, 2017 Apr.
[Is] ISSN:1534-4436
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler (pMDI) have been demonstrated in patients with asthma at least 12 years old. OBJECTIVE: To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in children 6 to younger than 12 years with asthma. METHODS: This randomized, double-blinded, parallel-group, multicenter study (NCT02091986; CHASE 3) included children 6 to younger than 12 years with asthma previously receiving a medium-dose inhaled corticosteroid (ICS) or an ICS plus a long-acting ß -agonist. Children symptomatic during a 7-28-day run-in on low-dose ICS, 1 inhalation of budesonide dry powder inhaler 90 µg twice daily (BID), were randomized to receive 2 inhalations of budesonide/formoterol pMDI 80/4.5 µg (160/9 µg) BID (n = 92), budesonide/formoterol pMDI 80/2.25 µg (160/4.5 µg) BID (n = 95), or budesonide pMDI 80 µg (160 µg) BID (n = 92) for 12 weeks. RESULTS: Change in forced expiratory volume in 1 second from baseline to 1 hour after dosing (primary end point), change in forced expiratory volume in 1 second 15 minutes after dosing, and peak expiratory flow 1 hour after dosing at week 12 were statistically significantly greater for budesonide/formoterol 160/9 µg vs budesonide (P ≤ .015 for all comparisons), but not for budesonide/formoterol 160/4.5 µg vs budesonide. Bronchodilator effects, evident 15 minutes after the dose on day 1, were maintained at week 12. Incidence of protocol-defined asthma exacerbations and improvements in asthma symptom-related and quality-of-life outcomes were similar across treatments. There were no notable safety differences among treatments. CONCLUSION: Budesonide/formoterol pMDI 160/9 µg showed statistically significant and clinically meaningful lung function improvements vs budesonide pMDI 160 µg, demonstrating appropriateness as a therapeutic option for children 6 to younger than 12 years with asthma symptomatic on ICS alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02091986.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Budesonida/uso terapêutico
Etanolaminas/uso terapêutico
Fumarato de Formoterol/administração & dosagem
[Mh] Termos MeSH secundário: Antiasmáticos/administração & dosagem
Asma/fisiopatologia
Budesonida/administração & dosagem
Budesonida/efeitos adversos
Criança
Quimioterapia Combinada
Etanolaminas/administração & dosagem
Etanolaminas/efeitos adversos
Feminino
Volume Expiratório Forçado
Seres Humanos
Masculino
Inaladores Dosimetrados
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Ethanolamines); 51333-22-3 (Budesonide); W34SHF8J2K (Formoterol Fumarate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE



página 1 de 149 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde